Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
One pharmaceutical company may be heading toward a cure for sickle cell disease.
Bluebird Bio presented promising results for its experimental gene therapy drug at the American Society of Hematology Annual Meeting. Its LentiGlobin treatment is still in the early stages of a clinical study, but the data showed encouraging signs to fix a debilitating disease.
Sickle cell disease is a genetic disorder that slows or stops blood flow. Bluebird's treatment essentially restores a patient's cells and allows the person's body to produce the appropriate protein for life, CEO Nick Leschly explained to CNBC on Monday.
One patient apparently went for a three-mile run after taking the treatment, Leschly said, which people with sickle cell disease normally can't do. Despite the early indications, Bluebird is cautious in calling the drug a cure so it doesn't promise too much "because patients are sitting there really looking for options," he said.
"So we're a little bit careful with that, but that's absolutely within the reach. It is definitely a potential," he said.
Because gene therapy is an emerging treatment option, Leschly says an appropriate payment system hasn't been established. Today, patients typically pay for multiple drug doses over a long period of time, Leschly said. Bluebird's sickle cell disease drug would differ because it's a one-time treatment. That could produce a sense of sticker shock.
To combat that, Leschly suggests moving toward a value-based system where multiple parties share the risk over time. If the treatment works, they pay. If it doesn't, they don't.
"We're talking about doing it one time now, so it's perhaps less about that one-time, up-front payment and more about how we do this over time and sharing that risk over time, then I think you can get out of that sticker shock," he said. "But it is a challenge for the system, and the system's not ready, we'll freely admit that."
Politicians, including President Donald Trump, have assailed the pharmaceutical industry for charging high prices.
Bluebird will consider cost and access when pricing the drug, Leschly said, noting that a large population of sickle cell patients are insured through Medicaid. As for timing, he said part of it depends on regulators, though Bluebird will be as aggressive as possible in getting it cleared.
Shares of Bluebird soared 24 percent on Monday.